mAbs against interleukin-6, B-cell activating factor CD138, Dickkopf 1 (DKK1), receptor activator of nuclear factor-κB ligand (RANKL), SLAMF7, and CD38 are currently in clinical development for the treatment of multiple myeloma [14]. This evidence concerns the gene SLAMF7 and plasma cell myeloma.